Table 1 Characteristic of patients
All patients (n = 61) | Survivor (n = 41) | Non-survivor (n = 20) | p value | |
|---|---|---|---|---|
Male, n | 37 (60.7%) | 22 (53.7%) | 15 (75%) | 0.163 |
Female, n | 24 (39.3%) | 19 (46.3%) | 5 (25%) | 0.163 |
Age, years | 63 (21–88) | 63 (21–88) | 67 (53-85) | 0.293 |
SOFA | 11 (± 4) | 10 (± 3.8) | 14 (± 3.2) | 0.0002 |
SAPS II | 54 (± 19) | 47 (± 16.6) | 68 (± 16.9) | 0.002 |
ICU-mortality, n | 19 (31.2%) | |||
Hospital mortality, n | 15 (23.4%) | |||
Pneumonia, n | 23 (37.7%) | 15 (36.6%) | 8 (40%) | 0.990 |
Urinary tract infection, n | 6 (12.8%) | 5 (12.2%) | 1 (5%) | 0.654 |
Acute abdominal infection, n | 6 (9.8%) | 3 (7.3%) | 3 (15%) | 0.384 |
Skin or soft tissue infection, n | 6 (9.8%) | 4 (9.8%) | 2 (10%) | 0.990 |
Blood catheter infection, n | 2 (4.3%) | 2 (4.8%) | 0 | 0.990 |
Implant infection, n | 1 (2.1%) | 1 (2.4%) | 0 | 0.990 |
Others, n | 6 (9.8%) | 3 (7.3%) | 3 (15%) | 0.384 |
Multiple foci, n | 11 (18.0%) | 6 (14.6%) | 5 (25%) | 0.479 |
patients with malignant diseases, n | 11 (18.0%) | 6 (14.6%) | 5 (25%) | 0.479 |
Septic shock, n | 47 (77.1%) | 28 (68.3%) | 19 (95%) | 0.024 |
Immunosuppresive co-medication, n | 26 (41.0%) | 15 (36.6%) | 11 (55%) | 0.270 |
Red blood cell transfusion (within 3 months before admission, n) | 18 (29.5%) | 7 (17.0%) | 11 (55%) | 0.006 |